Search research articles
Contact Us
Filters
Showing results (31-40 of 105) with videos related to
Page
of 11
Sort By:
Annals of Neurology
|
December 26, 2015
Reply
Seward B Rutkove, Jeremy M Shefner, Robert Bowser, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
August 20, 2013
A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis
Jeremy M Shefner, Mary Lou Watson, Lisa Meng, et al.
Annals of Neurology
|
February 1, 2021
To Zoom or Not to Zoom: The Should I Travel Index Revisited during the Coronavirus Disease Pandemic
Seward B Rutkove, Jeremy M Shefner, Robert Bowser, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
September 12, 2017
Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance
Lisa Meng, Amy Bian, Scott Jordan, et al.
The American Journal of Managed Care
|
April 26, 2018
Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion
Benjamin Rix Brooks, James A Jorgenson, Barbara J Newhouse, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
November 30, 2018
ALS longitudinal studies with frequent data collection at home: study design and baseline data
Seward B Rutkove, Kristin Qi, Kerisa Shelton, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
September 20, 2023
Harmonized standard operating procedures for administering the ALS functional rating scale-revised
Jeremy M Shefner, Tommy Bunte, Gale Kittle, et al.
Epidemiology (Cambridge, Mass.)
|
April 20, 2002
Lead exposure and amyotrophic lateral sclerosis
Freya Kamel, David M Umbach, Theodore L Munsat, et al.
Neurology
|
July 8, 2016
Quantitative strength testing in ALS clinical trials
Jeremy M Shefner, Dawei Liu, Melanie L Leitner, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
March 17, 2016
A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis
Jeremy M Shefner, Andrew A Wolff, Lisa Meng, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 105) with videos related to
Sort By:
Page
of 11
Annals of Neurology
|
December 26, 2015
Reply
Seward B Rutkove, Jeremy M Shefner, Robert Bowser, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
August 20, 2013
A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis
Jeremy M Shefner, Mary Lou Watson, Lisa Meng, et al.
Annals of Neurology
|
February 1, 2021
To Zoom or Not to Zoom: The Should I Travel Index Revisited during the Coronavirus Disease Pandemic
Seward B Rutkove, Jeremy M Shefner, Robert Bowser, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
September 12, 2017
Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance
Lisa Meng, Amy Bian, Scott Jordan, et al.
The American Journal of Managed Care
|
April 26, 2018
Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion
Benjamin Rix Brooks, James A Jorgenson, Barbara J Newhouse, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
November 30, 2018
ALS longitudinal studies with frequent data collection at home: study design and baseline data
Seward B Rutkove, Kristin Qi, Kerisa Shelton, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
September 20, 2023
Harmonized standard operating procedures for administering the ALS functional rating scale-revised
Jeremy M Shefner, Tommy Bunte, Gale Kittle, et al.
Epidemiology (Cambridge, Mass.)
|
April 20, 2002
Lead exposure and amyotrophic lateral sclerosis
Freya Kamel, David M Umbach, Theodore L Munsat, et al.
Neurology
|
July 8, 2016
Quantitative strength testing in ALS clinical trials
Jeremy M Shefner, Dawei Liu, Melanie L Leitner, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
March 17, 2016
A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis
Jeremy M Shefner, Andrew A Wolff, Lisa Meng, et al.
Page
of 11